Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 474

1.
2.

Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.

Fu DJ, Bossie CA, Kern Sliwa J, Ma YW, Alphs L.

Clin Schizophr Relat Psychoses. 2014 Jul;8(2):101-9, 109A. doi: 10.3371/CSRP.FUBO.022213.

PMID:
23446197
3.

Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.

Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, Coppola D, Schotte A, Remmerie B, Maruta N, Hough DW.

JAMA Psychiatry. 2015 Aug;72(8):830-9. doi: 10.1001/jamapsychiatry.2015.0241.

PMID:
25820612
4.

A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.

Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, Kusumakar V, Yuen E, Palumbo J.

J Clin Psychopharmacol. 2010 Jun;30(3):235-44. doi: 10.1097/JCP.0b013e3181dd3103. Erratum in: J Clin Psychopharmacol. 2010 Aug;30(4):364.

PMID:
20473057
5.

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.

Li H, Rui Q, Ning X, Xu H, Gu N.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1002-8. doi: 10.1016/j.pnpbp.2011.02.001. Epub 2011 Feb 18.

PMID:
21315787
6.

Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.

Fu DJ, Bossie CA, Sliwa JK, Ma YW, Alphs L.

Int Clin Psychopharmacol. 2014 Jan;29(1):45-55. doi: 10.1097/YIC.0000000000000006.

PMID:
24113628
7.

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.

Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D.

J Psychopharmacol. 2011 May;25(5):685-97. doi: 10.1177/0269881110372817. Epub 2010 Jul 8.

PMID:
20615933
8.

Paliperidone palmitate for schizophrenia.

Nussbaum AM, Stroup TS.

Cochrane Database Syst Rev. 2012 Jun 13;(6):CD008296. doi: 10.1002/14651858.CD008296.pub2. Review.

PMID:
22696377
9.

Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.

Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, Eerdekens MH, Brown DW.

Int Clin Psychopharmacol. 2010 Sep;25(5):247-56. doi: 10.1097/YIC.0b013e32833948fa.

PMID:
20389255
10.

A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.

Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, Yuen E, Hough D.

Neuropsychopharmacology. 2010 Sep;35(10):2072-82. doi: 10.1038/npp.2010.79. Epub 2010 Jun 16.

11.

Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.

McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, Ray N, Lamberti JS, Buckley PF, Wilkins TM, Stroup TS.

JAMA. 2014 May 21;311(19):1978-87. doi: 10.1001/jama.2014.4310. Erratum in: JAMA. 2014 Oct 8;312(14):1473.

12.

Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.

Sliwa JK, Bossie CA, Ma YW, Alphs L.

Schizophr Res. 2011 Oct;132(1):28-34. doi: 10.1016/j.schres.2011.06.016. Epub 2011 Jul 20.

PMID:
21775106
14.

Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.

Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V, Yuen E, Eerdekens M.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 31;33(6):1022-31. doi: 10.1016/j.pnpbp.2009.05.014. Epub 2009 May 28.

PMID:
19481579
15.

A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.

Fleischhacker WW, Gopal S, Lane R, Gassmann-Mayer C, Lim P, Hough D, Remmerie B, Eerdekens M.

Int J Neuropsychopharmacol. 2012 Feb;15(1):107-18. doi: 10.1017/S1461145711001076. Epub 2011 Jul 22. Erratum in: Int J Neuropsychopharmacol. 2012 Feb;15(1):119. Dosage error in article text.

PMID:
21777507
16.

Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.

Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L.

Curr Med Res Opin. 2010 Feb;26(2):377-87. doi: 10.1185/03007990903482772. Review.

PMID:
20001492
17.

Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.

Carter NJ.

Drugs. 2012 May 28;72(8):1137-60. doi: 10.2165/11208640-000000000-00000.

PMID:
22571444
19.

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.

Turkoz I, Bossie CA, Lindenmayer JP, Schooler N, Canuso CM.

BMC Psychiatry. 2011 Feb 7;11:21. doi: 10.1186/1471-244X-11-21.

20.

Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.

Alphs L, Benson C, Cheshire-Kinney K, Lindenmayer JP, Mao L, Rodriguez SC, Starr HL.

J Clin Psychiatry. 2015 May;76(5):554-61. doi: 10.4088/JCP.14m09584.

Supplemental Content

Support Center